Darexaban

DB12289InvestigationalSmall molecule

Darexaban has been used in trials studying the prevention and basic science of Japanese, Caucasian, Thromboembolism, Pharmacodynamics, and Pharmacokinetics, among others.

Mechanism: Pharmacologically active on Coagulation factor X
Curator reviewed
Formula / weight: C₂₇H₃₀N₄O₄ · 474.561 g/mol (avg)
Code names: YM-150

Resolves to

Compound

UNIIKF322K101SCAS365462-23-3ChEMBLCHEMBL1922235PubChem9912771

Structure

InChIKeyIJNIQYINMSGIPS-UHFFFAOYSA-NSMILESCOC1=CC=C(C=C1)C(=O)NC1=C(NC(=O)C2=CC=C(C=C2)N2CCCN(C)CC2)C(O)=CC=C1

Targets

P00742F10

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

642Drug interactionsStructured to mechanism, not free text

15Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Darexaban, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account